HLA-C and cancer: Another breakthrough in cancer immunotherapy occurred when chimeric antigen receptor T-cells (CAR T) were introduced as an MHC-independent adaptive T-cell therapy [4], making those cell products easier to generate by using principles of synthetic biology [1].